Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

C4 Therapeutics blasts off: what's next?

C4 Therapeutics suck price outlook

As the market soars to new heights, with capital fast flowing back into the small-cap, more speculative, and traditionally risky investments and sectors, C4 Therapeutics (NASDAQ: CCCC) has become the latest small-cap stock to surge higher in price.

With the iShares Russell 2000 ETF (NYSE: IWM) up more than 5% last week and over 10% on the month, investor's appetite for speculative investments has grown. It’s important to remember that the year-to-date theme has seen small caps, and the IWM trail the rest of the market. 

However, that is no longer the case, as the IWM has notably outperformed the overall market and even the market's strongest year-to-date sector, the technology sector, so far this month.

So amidst the surge of small-cap stocks, where prices are climbing, trading volumes are up, and they're gaining serious attention, it's worth zooming in on the standout small-cap that shot up last week. Let’s figure out if it's a potential investment gem, or another small-cap swept up in the market's excitement and short-lived trading actions.

What is C4 Therapeutics?

C4 Therapeutics stock outlook

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focusing on innovative therapies targeting disease-causing proteins in cancer, neurodegenerative disorders, and other ailments. Their leading candidate, CFT7455, is undergoing Phase 1/2 trials for multiple myeloma and various lymphomas. Additionally, the company is developing treatments like CFT8634 for synovial sarcoma and CFT1946 for melanoma, NSCLC, and other solid tumors. They also collaborate with Roche, Biogen, and Calico Life Sciences.

C4’s stock, appropriately named ‘CCCC,’ has an average daily trading volume of 3.41 million shares. The company has a market capitalization of just over $240 million. As of last week’s close, the stock was trading in the midpoint of its 52-week range and the high-end of its 50-day range. 

Why C4 stock exploded higher last week

C4 Therapeutics witnessed a significant surge in its stock on last Tuesday due to an exciting partnership announcement with Merck (NYSE: MRK), a renowned pharmaceutical company. 

This exclusive collaboration focuses on developing degrader-antibody conjugates (DACs), a promising approach to target and combat disease-causing proteins in cancer cells. The deal involves C4 Therapeutics receiving an upfront payment of $10 million from Merck, with potential milestone payments totaling up to $600 million, alongside tiered royalties from future sales. 

Within this partnership, C4 Therapeutics will utilize its Torpedo platform to create degrader payloads during the discovery phase, while Merck will handle the antibody conjugation process to form DACs. Merck will then proceed with clinical trials and commercializing these innovative treatments. 

Andrew Hirsch, President and CEO of C4 Therapeutics, expressed enthusiasm about the collaboration, highlighting the potential to develop groundbreaking medicines that could make a profound difference in patients' lives.

Where’s the stock heading?

With the breaking news came an enormous surge in price for the stock and trading volume. The stock traded over 600 million shares last week, versus its average daily trading volume of just 3.4 million shares. 

While the consensus analyst price target of $9.60, suggesting nearly a 100% upside, might seem exaggerated, it's crucial not to overlook the significance of last week's trading volume. Although it's uncertain whether the collaboration will fundamentally alter the company's trajectory in the long run, the recent surge in trading volume could fuel additional short-term volatility. Consequently, this could position it as a favorable trading vehicle rather than a stable investment vehicle.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.